Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADMYRE: Plitidepsin + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01102426Phase 3Completed
- Sponsor
- PharmaMar
- Start
- Jun 2010
- Primary completion
- Nov 2017
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of plitidepsin in multiple myeloma (MM) (2 arms), sponsored by PharmaMar. Primary endpoints: Progression Free Survival at 5 years and Percentage of Participants With Progression Free Survival at 6 months. Started Jun 2010; status: completed.
02
Drugs
plitidepsin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01102426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01102426.